PMID- 33252786
OWN - NLM
STAT- MEDLINE
DCOM- 20210906
LR  - 20210906
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 149
IP  - 1
DP  - 2021 Jul 1
TI  - Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade 
      immunotherapy combinations?
PG  - 31-41
LID - 10.1002/ijc.33415 [doi]
AB  - Immunotherapy approaches boosting spontaneous and durable antitumor immune 
      responses through immune checkpoint blockade are revolutionizing treatment and 
      patient outcomes in solid tumors and hematological malignancies. Among the 
      various inhibitory molecules employed by the immune system to regulate the 
      adaptive immune responses, cytotoxic T lymphocyte antigen-4 (CTLA-4) is the first 
      successfully targeted immune checkpoint molecule in the clinic, giving rise to 
      significant but selective benefit either when targeted alone or in combination 
      with anti-programmed cell death protein-1 (PD-1) antibodies (Abs). However, the 
      use of anti-CTLA-4 Abs was associated with the incidence of autoimmune-like 
      adverse events (AEs), which were particularly frequent and severe with the use of 
      combinational strategies. Nevertheless, the higher incidence of AEs is associated 
      with an improved clinical benefit indicating treatment response. A prompt 
      recognition of AEs followed by early and adequate treatment with 
      immunosuppressive agents allows the management of these potentially serious AEs. 
      This narrative review aims to summarize CTLA-4 biology, the rationale for the use 
      as a companion for anti-PD-1 Abs in humans with results from the most relevant 
      Phase III clinical trials including anti-CTLA-4 Abs in combination with anti-PD-1 
      Abs in solid tumors.
CI  - (c) 2020 UICC.
FAU - De Silva, Pushpamali
AU  - De Silva P
AD  - Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard 
      Medical School, Boston, Massachusetts, USA.
FAU - Aiello, Marco
AU  - Aiello M
AUID- ORCID: 0000-0002-3386-9189
AD  - Medical Oncology Unit A.O.U. Policlinico, Vittorio Emanuele di Catania, Catania, 
      Italy.
FAU - Gu-Trantien, Chunyan
AU  - Gu-Trantien C
AD  - Institute of Medical Immunology, Universite Libre de Bruxelles, Brussels, 
      Belgium.
FAU - Migliori, Edoardo
AU  - Migliori E
AD  - Columbia University Medical Center, Columbia Center for Translational Immunology, 
      New York, New York, USA.
FAU - Willard-Gallo, Karen
AU  - Willard-Gallo K
AD  - Molecular Immunology Unit, Institut Jules Bordet, Bruxelles, Belgium.
FAU - Solinas, Cinzia
AU  - Solinas C
AUID- ORCID: 0000-0001-6782-8708
AD  - Regional Hospital of Valle d'Aosta, Azienda U.S.L. Valle d'Aosta, Aosta, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201221
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (CTLA-4 Antigen)
RN  - 0 (CTLA4 protein, human)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - CTLA-4 Antigen/*antagonists & inhibitors
MH  - Humans
MH  - Immunity
MH  - Immunotherapy/*methods
MH  - *Molecular Targeted Therapy
MH  - Neoplasms/*drug therapy/immunology/metabolism/pathology
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors
OTO - NOTNLM
OT  - CTLA-4
OT  - PD-1
OT  - immune checkpoint blockade
OT  - immune checkpoints
OT  - immune-related adverse events
OT  - immunotherapy
EDAT- 2020/12/01 06:00
MHDA- 2021/09/07 06:00
CRDT- 2020/11/30 12:12
PHST- 2020/10/25 00:00 [revised]
PHST- 2020/06/04 00:00 [received]
PHST- 2020/10/28 00:00 [accepted]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2021/09/07 06:00 [medline]
PHST- 2020/11/30 12:12 [entrez]
AID - 10.1002/ijc.33415 [doi]
PST - ppublish
SO  - Int J Cancer. 2021 Jul 1;149(1):31-41. doi: 10.1002/ijc.33415. Epub 2020 Dec 21.